Celera licenses lung cancer IP from Medical Therapies
Celera has entered an exclusive license agreement with Medical Therapies for the use of their midkine patent portfolio for the development of novel lung cancer diagnostics. The terms of the license include upfront and milestone payments and royalties on net product sales for the life of the relevant patents. Additional financial details of the agreement were not disclosed. :theflyonthewall.com
News For CRA From The Last 14 Days
Check below for free stories on CRA the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
